BioRx Enters the Alpha-1 Specialty Home Infusion Market
10/13/2010 10:09:42 AM
CINCINNATI--(BUSINESS WIRE)--BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as “genetic” or “congenital” emphysema.
comments powered by